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EDITORIAL
Extracranial Stereotactic Body Radiotherapy for Stage I
Non-small Cell Lung Cancer
Still Investigational or Standard of Care?
David Ball, MD, FRANZCR
Once shunned by radiation oncologists when prescribing high dose radiotherapybecause of its association with serious late toxicity, hypofractionation seems to be
making a comeback. The use of a reduced number of large doses per fraction to deliver
radical treatment is increasingly under investigation in early stage breast, prostate and now
non-small cell lung cancer.
In stage I non-small cell lung cancer, schedules consisting of 3 or more fractions of
12 to 20 Gy have been tested clinically in phase I and II trials.1 The delivery of these very
large doses has been made possible by greater treatment precision in which a large number
of multidirectional static (8) or dynamic beams are arranged to intersect at the locus of
the tumor. The dose contributed by each beam (and therefore to the normal tissues which
it traverses) is relatively small, but within the tumor, the summation of dose can result in
biologic effects - tumor ablation - theoretically only achievable with doses up to 180 Gy
given using conventional (2 Gy) fractionation.2 The theory is backed up by encouraging
rates of local control reported to be in excess of 85%.1
The generic term given to this treatment approach is extracranial stereotactic body
radiotherapy (SBRT). It is based on the principles established for the stereotactic
irradiation of intracranial tumors. The technical requirements are, however, different as
illustrated by the approach used at the Princess Margaret Hospital (PMH) in Toronto and
described in this issue of the journal.3
The term “stereotactic” implies that the treatment is guided by a set of external
three-dimensional coordinates derived from pretreatment localization of the tumor. How-
ever, the approach at PMH (as elsewhere) is not so much stereotactic as image guided.
That is, the beams are directed not by external coordinates but at the tumor itself which
is imaged immediately before each irradiation by a computed tomography scanner
attached to the treatment machine. Positional adjustments are then made to ensure that the
tumor is still within the high dose envelope as originally planned.
Another difference is that in the chest, unlike the brain, it is critically important to
be able to accurately record internal tumor motion secondary to physiological cardioven-
tilatory activity. If significant motion is detected, strategies need to be employed to ensure
the tumor does not move in and out of the treatment beam leading to underdosage
(“geographic miss”). These strategies include enlarging the target volume to encompass
all positions of the tumor during ventilation (but which increases the volume of normal
tissue irradiated); limiting the extent of ventilatory excursion, for example by abdominal
compression; and ventilatory gating. Although the PMH investigators document internal
tumor motion pretreatment (using 4D computed tomography), they found it necessary to
apply abdominal compression in fewer than 25% of patients, and like most other SBRT
groups, do not use gating at all.
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Now that the technical hurdles have been surmounted,
SBRT has been implemented both on and off investigational
protocols at a number of centers in North America and
Europe. Interestingly, this has happened in spite of an ab-
sence of supporting randomized phase III data. Given the
rapid uptake of this revolutionary new treatment approach,
we should pause to reflect on why conventional fractionation
came into use in the first place. It is well known that
hypofractionated radiotherapy using large doses per fraction
is associated with serious late normal tissue injury, and this
can be ameliorated by the use of conventional schedules
using 2 Gy per fraction. The safety of hypofractionated SBRT
came under the spotlight with a report from Indiana Univer-
sity.4 In that study, excessive toxicity was observed in pa-
tients with centrally located tumors, with the hypofraction-
ated treatment (60 Gy in 3 fractions) possibly contributing to
6 patient deaths. Chastened by this knowledge, the PMH
investigators and others5 have recommended a “gentler”
fractionation schedule (for example 60 Gy in 8 fractions) for
central tumors near the mediastinum. This is, however, no
guarantee that the treatment will be safe, as we have seen
radiation necrosis with even “gentler” schedules (42 Gy in 7
fractions) given to small volumes in the treatment of early
laryngeal cancer.6 Although the lung is not the larynx, carti-
lage, one of the tissues at risk, is a major structural compo-
nent of both organs.
Clinicians intoxicated by the heady mix of new tech-
nology and impressive rates of local control can be easily
persuaded that exceptional phase II data are sufficient to
change practice. However, it is my view that higher level
evidence is required before we can regard SBRT as a standard
of care. We only need to look at the recent history of
consolidation docetaxel in the treatment of locally advanced
disease to realize that what seems to be a world-beater in the
phase II setting may turn out to be a toxic also-ran when
subjected to the rigors of phase III evaluation.7 Let us hope
that is not the story of hypofractionated SBRT as well.
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